Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters
Objectives: The efficacy of BIC/FTC/TAF in HIV late presenters initiating antiretroviral therapy (ART) has not been sufficiently evaluated. Methods: The aim of this study was to assess the effectiveness and tolerability of BIC/FTC/TAF compared to other first-line antiretroviral regimens in treatment...
| Autores: | , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Instituto de Salud Carlos III (ISCIII) |
| Repositorio: | Repisalud |
| Idioma: | inglés |
| OAI Identifier: | oai:repisalud.isciii.es:20.500.12105/18995 |
| Acceso en línea: | http://hdl.handle.net/20.500.12105/18995 |
| Access Level: | acceso abierto |
| Palabra clave: | Anti-HIV Agents Acquired Immunodeficiency Syndrome HIV Infections Piperazines Pyridones Alanine Amides Heterocyclic Compounds, 3-Ring Adult Male Humans Female Drug Combinations Emtricitabine Tenofovir |
| id |
ES_3fc07524b32042a2b375d0b93bc973ea |
|---|---|
| oai_identifier_str |
oai:repisalud.isciii.es:20.500.12105/18995 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presentersCorona, DianaPérez-Valero, IgnacioCamacho, AngelaGutiérrez Liarte, ÁngelaMontero-Alonso, MartaAlemán, María RemediosRuiz-Seco, PilarPérez González, AlexandreRiera, MelchorJarrin Vera, InmaculadaRivero-Juarez, AntonioRivero, AntonioAnti-HIV AgentsAcquired Immunodeficiency SyndromeHIV InfectionsPiperazinesPyridonesAlanineAmidesHeterocyclic Compounds, 3-RingAdultMaleHumansFemaleDrug CombinationsEmtricitabineTenofovirObjectives: The efficacy of BIC/FTC/TAF in HIV late presenters initiating antiretroviral therapy (ART) has not been sufficiently evaluated. Methods: The aim of this study was to assess the effectiveness and tolerability of BIC/FTC/TAF compared to other first-line antiretroviral regimens in treatment-naïve adult individuals from the CoRIS Cohort starting ART with CD4 counts <200 cells/mm3 and/or AIDS-defining conditions between January 1st 2019 and November 30th 2020. Logistic regression models were used to estimate odds ratios (ORs) of association between initial regimen and achievement of viral suppression (VS) (primary objective), defined as HIV RNA <50 cop/mL, and immunological recovery (IR) (secondary objective), defined as CD4 count >200 cells/mm3, at weeks 24 and 48 after initiation of ART. Results: We evaluated 314 individuals (84.7% men, median age 40 years). Of them, 158 initiated with BIC/FTC/TAF. At inclusion, 117 had an AIDS-defining condition. In multivariable analyses, individuals with AIDS-defining conditions initiating ART with BIC/FTC/TAF achieved higher rates of VS at 24 weeks than other regimens (aOR: 0.2; 95% CI: 0.06-0.64) and, at 48 weeks, than DTG/ABC/3TC (aOR: 0.06; 95% CI: 0.01-0.76) and DTG + TDF/3TC (aOR: 0.2; 95% CI: 0.47-0.9). No other differences in VS or IR were observed. At 24 and 48 weeks after ART initiation, treatment discontinuations were lower with BIC/FTC/TAF than with other regimens (3.2% and 7.6% vs. 24.4% and 37.8%, respectively; P < 0.005). Conclusion: Our results suggest that BIC/FTC/TAF could be a preferred regimen as initial therapy in HIV late presenters because of its high effectiveness and good tolerability.ElsevierGilead Sciences (Spain)Ministerio de Sanidad (España)Plan Nacional de I+D+i (España)Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)Instituto de Salud Carlos IIIUnión Europea. Comisión Europea. NextGenerationEUMinisterio de Ciencia e Innovación (España)Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)20242024-03-1820242024-01-0120242024-01-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfapplication/pdfhttp://hdl.handle.net/20.500.12105/18995reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/189952026-06-12T12:43:37Z |
| dc.title.none.fl_str_mv |
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters |
| title |
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters |
| spellingShingle |
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters Corona, Diana Anti-HIV Agents Acquired Immunodeficiency Syndrome HIV Infections Piperazines Pyridones Alanine Amides Heterocyclic Compounds, 3-Ring Adult Male Humans Female Drug Combinations Emtricitabine Tenofovir |
| title_short |
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters |
| title_full |
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters |
| title_fullStr |
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters |
| title_full_unstemmed |
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters |
| title_sort |
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters |
| dc.creator.none.fl_str_mv |
Corona, Diana Pérez-Valero, Ignacio Camacho, Angela Gutiérrez Liarte, Ángela Montero-Alonso, Marta Alemán, María Remedios Ruiz-Seco, Pilar Pérez González, Alexandre Riera, Melchor Jarrin Vera, Inmaculada Rivero-Juarez, Antonio Rivero, Antonio |
| author |
Corona, Diana |
| author_facet |
Corona, Diana Pérez-Valero, Ignacio Camacho, Angela Gutiérrez Liarte, Ángela Montero-Alonso, Marta Alemán, María Remedios Ruiz-Seco, Pilar Pérez González, Alexandre Riera, Melchor Jarrin Vera, Inmaculada Rivero-Juarez, Antonio Rivero, Antonio |
| author_role |
author |
| author2 |
Pérez-Valero, Ignacio Camacho, Angela Gutiérrez Liarte, Ángela Montero-Alonso, Marta Alemán, María Remedios Ruiz-Seco, Pilar Pérez González, Alexandre Riera, Melchor Jarrin Vera, Inmaculada Rivero-Juarez, Antonio Rivero, Antonio |
| author2_role |
author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Gilead Sciences (Spain) Ministerio de Sanidad (España) Plan Nacional de I+D+i (España) Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) Instituto de Salud Carlos III Unión Europea. Comisión Europea. NextGenerationEU Ministerio de Ciencia e Innovación (España) Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas) |
| dc.subject.none.fl_str_mv |
Anti-HIV Agents Acquired Immunodeficiency Syndrome HIV Infections Piperazines Pyridones Alanine Amides Heterocyclic Compounds, 3-Ring Adult Male Humans Female Drug Combinations Emtricitabine Tenofovir |
| topic |
Anti-HIV Agents Acquired Immunodeficiency Syndrome HIV Infections Piperazines Pyridones Alanine Amides Heterocyclic Compounds, 3-Ring Adult Male Humans Female Drug Combinations Emtricitabine Tenofovir |
| description |
Objectives: The efficacy of BIC/FTC/TAF in HIV late presenters initiating antiretroviral therapy (ART) has not been sufficiently evaluated. Methods: The aim of this study was to assess the effectiveness and tolerability of BIC/FTC/TAF compared to other first-line antiretroviral regimens in treatment-naïve adult individuals from the CoRIS Cohort starting ART with CD4 counts <200 cells/mm3 and/or AIDS-defining conditions between January 1st 2019 and November 30th 2020. Logistic regression models were used to estimate odds ratios (ORs) of association between initial regimen and achievement of viral suppression (VS) (primary objective), defined as HIV RNA <50 cop/mL, and immunological recovery (IR) (secondary objective), defined as CD4 count >200 cells/mm3, at weeks 24 and 48 after initiation of ART. Results: We evaluated 314 individuals (84.7% men, median age 40 years). Of them, 158 initiated with BIC/FTC/TAF. At inclusion, 117 had an AIDS-defining condition. In multivariable analyses, individuals with AIDS-defining conditions initiating ART with BIC/FTC/TAF achieved higher rates of VS at 24 weeks than other regimens (aOR: 0.2; 95% CI: 0.06-0.64) and, at 48 weeks, than DTG/ABC/3TC (aOR: 0.06; 95% CI: 0.01-0.76) and DTG + TDF/3TC (aOR: 0.2; 95% CI: 0.47-0.9). No other differences in VS or IR were observed. At 24 and 48 weeks after ART initiation, treatment discontinuations were lower with BIC/FTC/TAF than with other regimens (3.2% and 7.6% vs. 24.4% and 37.8%, respectively; P < 0.005). Conclusion: Our results suggest that BIC/FTC/TAF could be a preferred regimen as initial therapy in HIV late presenters because of its high effectiveness and good tolerability. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024 2024-03-18 2024 2024-01-01 2024 2024-01-01 |
| dc.type.none.fl_str_mv |
research article http://purl.org/coar/resource_type/c_2df8fbb1 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/20.500.12105/18995 |
| url |
http://hdl.handle.net/20.500.12105/18995 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:Repisalud instname:Instituto de Salud Carlos III (ISCIII) |
| instname_str |
Instituto de Salud Carlos III (ISCIII) |
| reponame_str |
Repisalud |
| collection |
Repisalud |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869406675095519232 |
| score |
15.812429 |